Effects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women
- PMID: 26357648
- PMCID: PMC4561737
- DOI: 10.6118/jmm.2015.21.2.104
Effects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women
Abstract
Objectives: This study was conducted to examine the effects of hormone therapy on serum lipid levels in postmenopausal Korean women.
Methods: This retrospective cohort study included 154 healthy postmenopausal Korean women. Seventy-nine women took oral estrogen (conjugated equine estrogen 0.625 mg/day or equivalent), and 75 applied estrogen transdermally using 0.1% 17β-estradiol gel. Micronized progesterone (MP) was added to 40 women of oral group and 49 women in transdermal group. Serum levels of triglyceride, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and lipoprotein (a) were measured before, 3 and 6 month after hormone therapy.
Results: At baseline, mean body mass index (BMI) were lower (22.76 vs. 23.74 kg/m(2)) and proportion of family history of cardiovascular disease (CVD) (61 vs. 39%) were higher in oral group. In oral group, LDL-C and lipoprotein(a) levels decreased, and triglyceride and HDL-C levels increased significantly after 3 and 6 months. There was no significant change in lipoprotein levels compared to the baseline in transdermal group. There were also no differences with additional MP. Changing pattern of HDL-C during 6 months was significantly different by the route of estrogen administration.
Conclusion: Oral estrogen therapy might be more beneficial than transdermal estrogen in terms of lipid in postmenopausal Korean women. The estrogen effects are not influenced by adding MP.
Keywords: Drug administration route; Hormone replacement therapy; Lipids; Progesterone.
Conflict of interest statement
Figures

Similar articles
-
Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial.Lipids Health Dis. 2012 Oct 9;11:133. doi: 10.1186/1476-511X-11-133. Lipids Health Dis. 2012. PMID: 23046709 Free PMC article. Clinical Trial.
-
Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.Climacteric. 2002 Sep;5(3):286-92. Climacteric. 2002. PMID: 12419087 Clinical Trial.
-
Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol.Arch Gynecol Obstet. 1998;261(4):201-8. doi: 10.1007/s004040050222. Arch Gynecol Obstet. 1998. PMID: 9789651
-
[Investigation of atherosclerosis in postmenopausal women: alteration of atherosclerosis-associated factors and vascular atherosclerosis by oral and transdermal estrogen replacement].Rinsho Byori. 2013 Mar;61(3):256-62. Rinsho Byori. 2013. PMID: 23785796 Review. Japanese.
-
Spotlight on estradiol and norgestimate as hormone replacement therapy in postmenopausal women.Treat Endocrinol. 2002;1(2):127-9. doi: 10.2165/00024677-200201020-00006. Treat Endocrinol. 2002. PMID: 15765628 Review.
Cited by
-
Predominance of Heart Failure With Preserved Ejection Fraction in Postmenopausal Women: Intra- and Extra-Cardiomyocyte Maladaptive Alterations Scaffolded by Estrogen Deficiency.Front Cell Dev Biol. 2021 Sep 29;9:685996. doi: 10.3389/fcell.2021.685996. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34660569 Free PMC article. Review.
-
17β-Estradiol Inhibits PCSK9-Mediated LDLR Degradation Through GPER/PLC Activation in HepG2 Cells.Front Endocrinol (Lausanne). 2020 Jan 30;10:930. doi: 10.3389/fendo.2019.00930. eCollection 2019. Front Endocrinol (Lausanne). 2020. PMID: 32082252 Free PMC article.
-
Differential Effects of Estradiol and Progesterone on Cardiovascular Risk Factors in Postmenopausal Women.J Endocr Soc. 2018 Jun 14;2(7):794-805. doi: 10.1210/js.2018-00073. eCollection 2018 Jul 1. J Endocr Soc. 2018. PMID: 29978153 Free PMC article.
-
Sex-Gender Disparities in Cardiovascular Diseases: The Effects of Estrogen on eNOS, Lipid Profile, and NFATs During Catecholamine Stress.Front Cardiovasc Med. 2021 Feb 12;8:639946. doi: 10.3389/fcvm.2021.639946. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 33644139 Free PMC article. Review.
-
Estrogen Protects Vasomotor Functions in Rats During Catecholamine Stress.Front Cardiovasc Med. 2021 Jun 16;8:679240. doi: 10.3389/fcvm.2021.679240. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34222374 Free PMC article.
References
-
- Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol. 2007;49:1230–1250. - PubMed
-
- Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791–798. - PubMed
-
- Bush TL. Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J. 1996;17(Suppl D):9–14. - PubMed
-
- Lee KS, Roh JS, Kim JG, Kim SH, Choi YM, Shin CJ, et al. The effect of ipriflavone on serum lipid profiles in postmenopausal women. J Korean Soc Menopause. 1996;2:27–35.
-
- Heo J, Park Y, Park HM. Dietary intake of nutrients and food in postmenopausal Korean women. J Korean Soc Menopause. 2011;17:12–20.
LinkOut - more resources
Full Text Sources
Other Literature Sources